Filing Details
- Accession Number:
- 0000950170-24-136782
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-16 17:56:45
- Reporting Period:
- 2024-12-12
- Accepted Time:
- 2024-12-16 17:56:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1160308 | Savara Inc | SVRA | Pharmaceutical Preparations (2834) | 841318182 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1573429 | Matthew Pauls | One Summit Square, 1717 Langhorne Newtown Road, Suite 300 Langhorne PA 19047 | Chief Executive Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-12-12 | 400,000 | $0.00 | 1,683,674 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2024-12-13 | 92,593 | $3.21 | 1,591,081 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2024-12-16 | 54,702 | $3.31 | 1,536,379 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2024-12-12 | 900,000 | $0.00 | 900,000 | $3.35 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 900,000 | 2034-12-12 | No | 4 | A | Direct |
Footnotes
- Represents restricted stock units ("RSUs") that vest in full on December 12, 2026, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- Represents shares sold to satisfy tax liability upon the vesting of restricted stock units.
- The price is a weighted average sales price. The sale prices ranged from $3.28 to $3.34. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 12, 2024, subject to the reporting person's continued service with the Issuer.
Billionaire Hedge Funds
